IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens

Journal of Immunology

Volumn 162, Issue 10, 1999, Pages 6141-6147

  Staats, Herman F ^a   Ennis, Francis A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD86 ANTIGEN; CHOLERA TOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; OVALBUMIN; PROTEIN; RECOMBINANT INTERLEUKIN 1ALPHA; RECOMBINANT INTERLEUKIN 1BETA; TETANUS TOXOID; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INTRANASAL DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MOUSE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; SERUM; VAGINA;

EID: 0033562987     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.162.10.6141     Document Type: Article

References (76)

1. Ogra, P. L. 1996. Mucosal immunoprophylaxis: an introductory overview. In Mucosal Vaccines. H. Kiyono, P. L. Ogra, and J. R. McGhee, eds. Academic Press, San Diego, p. 3.
2. Mowat, A. M. 1994. Oral tolerance and regulation of immunity to dietary antigens. In Handbook of Mucosal Immunology. P. L. Ogra, M. E. Lamm, J. R. McGhee, J. Mestecky, W. Strober, and J. Bienenstock, eds. Academic Press, San Diego, p. 185.
3. Husby, S., J. Mestecky, Z. Moldoveanu, S. Holland, and C. O. Elson. 1994. Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J. Immunol. 152:4663.
4. Staines, N. A., N. Harper, F. J. Ward, V. Malmstrom, R. Holmdahl, and S. Bansal. 1996. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal administration of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin. Exp. Immunol. 103:368.
5. Prakken, B. J., R. van der Zee, S. M. Anderton, P. J. S. van Kooten, W. Kuis, and W. V. Eden. 1997. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc. Natl. Acad. Sci. USA 94: 3284.
6. Hoyne, G. F., R. E. O'Hehir, D. C. Wraith, W. R. Thomas, and J. R. Lamb. 1993. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J. Exp. Med. 178:1783.
7. Zhu, J., G. M. Deng, M. Levi, B. Wahren, A. Diab, P. H. Vandermeide, and H. Link. 1998. Prevention of experimental autoimmune neuritis by nasal administration of P2 protein peptide 57-81. J. Neurol. Exp. Neurol. 57:291.
8. Xiao, B. G., and H. Link. 1997. Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin. Immunol. Immunopathol. 85:119.
9. Xu-Amano, J., H. Kiyono, R. J. Jackson, H. F. Staats, K. Fujihashi, P. D. Burrows, C. O. Elson, S. Pillai, and J. R. McGhee. 1993. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J. Exp. Med. 178:1309.
10. Staats, H. F., W. G. Nichols, and T. J. Palker. 1996. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J. Immunol. 157:462.
11. Staats, H. F., S. P. Montgomery, and T. J. Palker. 1997. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-Hiv antibody responses. AIDS Res. Hum. Retroviruses 13:945.
12. Wilson, A. D., A. Robinson, L. Irons, and C. R. Stokes. 1993. Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen. Vaccine 11:113.
13. Elson, C. O., and M. T. Dertzbaugh. 1994. Mucosal adjuvants. In Handbook of Mucosal Immunology. P. L. Ogra, M. E. Lamm, J. R. McGhee, J. Mestecky, W. Strober, and J. Bienenstock, eds. Academic Press, San Diego, p. 391.
14. Porgador, A., H. F. Staats, B. Faiola, E. Gilboa, and T. J. Palker. 1997. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J. Immunol. 158:834.
15. O'Hagan, D. T. 1997. Recent advances in vaccine adjuvants for systemic and mucosal adjuvants. J. Pharm. Pharmacol. 49:1.
16. Elson, C. O., and W. Ealding. 1984. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J. Immunol. 132:2736.
17. Elson, C. O., and W. Ealding. 1984. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J. Immunol. 133:2892.
18. Elson, C. O., S. Woogen, M. Gaspari, and W. Ealding. 1987. Induction of secretory IgA responses to protein antigens. Adv. Exp. Med. Biol. 216B:877.
19. Elson, C. O. 1996. Cholera toxin as a mucosal adjuvant. In Mucosal Vaccines. H. Kiyono, P. L. Ogra, and J. R. McGhee, eds. Academic Press, New York, p. 59.
20. Levine, M. M., J. B. Kaper, R. E. Black, and M. L. Clements. 1983. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47:510.
21. Snider, D. P., J. S. Marshall, M. H. Perdue, and H. Liang. 1994. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. J. Immunol. 153:647.
22. Marinaro, M., H. F. Staats, T. Hiroi, R. J. Jackson, M. Coste, P. N. Boyaka, N. Okahashi, M. Yamamoto, H. Kiyono, H. Bluethmann, et al. 1995. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155:4621.
23. Douce, G., M. Fontana, M. Pizza, R. Rappuoli, and G. Dougan. 1997. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65:2821.
24. Yamamoto, S., Y. Takeda, M. Yamamoto, H. Kurazono, K. Imaoka, M. Yamamoto, K. Fujihashi, M. Noda, H. Kiyono, and J. R. McGhee. 1997. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 185:1203.
25. Yamamoto, S., H. Kiyono, M. Yamamoto, K. Imaoka, M. Yamamoto, K. Fujihashi, F. W. Vanginkel, M. Noda, Y. Takeda, and J. R. McGhee. 1997. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. USA 94:5267.
26. Roberts, M., A. Bacon, R. Rappuoli, M. Pizza, I. Cropley, G. Douce, G. Dougan, M. Marinaro, J. McGhee, and S. Chatfield. 1995 Jun. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect. Immun. 63:2100.
27. Di Tommaso, A., G. Saletti, M. Pizza, R. Rappuoli, G. Dougan, S. Abrignani, G. Douce, and M. T. De Magistris. 1996. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 64:974.
28. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617.
29. Fontana, M. R., R. Manetti, V. Ciannelli, C. Magagnoli, A. Marchini, R. Olivieri, M. Domenighini, R. Rappuoli, and M. Pizza. 1995. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infect. Immun. 63:2336.
30. de Haan, L., W. R. Verweij, I. K. Feil, T. H. Lijnema, W. G. J. Hol, E. Agsteribbe, and J. Wilschut. 1996. Mutants of Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin. Infect. Immun. 64:5413.
31. Lycke, N., U. Karlsson, A. Sjolander, and K. E. Magnusson. 1991. The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand. J. Immunol. 33:691.
32. Wu, H. Y., and M. W. Russell. 1994. Comparison of systemic and mucosal priming for mucosal immune responses to a bacterial protein antigen given with or coupled to cholera toxin (CT) B subunit, and effects of pre-existing anti-CT immunity. Vaccine 12:215.
33. Chen, K.-S., and W. Strober. 1990. Cholera holotoxin and its B subunit enhance Peyer's patch B cell responses induced by orally administered influenza virus: disproportionate cholera toxin enhancement of the IgA B cell response. Eur. J. Immunol. 20:433.
34. Hornquist, E., and N. Lycke. 1993. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur. J. Immunol. 23:2136.
35. Cong, Y., C. T. Weaver, and C. O. Elson. 1997. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective upregulation of B7.2 expression. J. Immunol. 159:5301.
36. Bromander, A., J. Holmgren, and N. Lycke. 1991. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J. Immunol. 146:2908.
37. Kim, P.-H., L. Eckmann, W. J. Lee, W. Han, and M. F. Kagnoff. 1998. Cholera toxin and cholera toxin B subunit induce IgA switching through the action of TGF-β1. J. Immunol. 160:1198.
38. McGee, D. W., K. W. Beagley, W. K. Aicher, and J. R. McGhee. 1992. Transforming growth factor-β enhances interleukin-6 secretion by intestinal epithelial cells. Immunology 77:7.
39. McGee, D. W., K. W. Beagley, W. K. Aicher, and J. R. McGhee. 1993. Transforming growth factor-β and IL-1β act in synergy to enhance IL-6 secretion by the intestinal epithelial cell line, IEC-6. J. Immunol. 151:970.
40. McGee, D. W., T. Bamberg, S. J. Vitkus, and J. R. McGhee. 1995. A synergistic relationship between TNF-α, IL-1β, and TGF-β1 on IL-6 secretion by the IEC-6 intestinal epithelial cell line. Immunology 86:6.
41. Mascarenhas, J. O., M. E. Goodrich, H. Eichelberger, and D. W. McGee. 1996. Polarized secretion of IL-6 by IEC-6 intestinal epithelial cells: differential effects of IL-1β and TNF-α. Immunol. Invest. 25:333.
42. Parikh, A. A., A. L. Salzman, C. D. Kane, J. E. Fischer, and P. O. Hasselgren. 1997. IL-6 production in human intestinal epithelial cells following stimulation with IL-1β is associated with activation of the transcription factor NF-κB. J. Surg. Res. 69:139.
43. Parikh, A. A., A. L. Salzman, J. E. Fischer, C. Szabo, and P. O. Hasselgren. 1997. Interleukin-1β and interferon-γ regulate interleukin-6 production in cultured human intestinal epithelial cells. Shock 8:249.
44. Eckmann, L., H. C. Jung, C. Schurer-Maly, A. Panja, E. Morzycka-Wroblewska, and M. F. Kagnoff. 1993. Differential cytokine expression by human intestinal epithelial cell lines: regulated expression of interleukin 8. Gastroenterology 105: 1689.
45. Lin, R., P. E. Tarr, and T. C. Jones. 1995. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin. Infect. Dis. 21:1439.
46. Hakim, I., S. Levy, and R. Levy. 1996. A nine-amino acid peptide from IL-1-β augments antitumor immune responses induced by protein and DNA vaccines. J. Immunol. 157:5503.
47. Staruch, M. J., and D. D. Wood. 1983. The adjuvanticity of interleukin 1 in vivo. J. Immunol. 130:2191.
48. Nencioni, L., L. Villa, A. Tagliabue, G. Antoni, R. Presentini, F. Perin, S. Silvestri, and D. Boraschi. 1987. In vivo immunostimulating activity of the 163-171 peptide of human IL-1β. J. Immunol. 139:800.
49. Boraschi, D., L. Nencioni, L. Villa, S. Censini, P. Bossu, P. Ghiara, R. Presentini, F. Perin, D. Frasca, G. Doria, et al. 1988. In vivo stimulation and restoration of the immune response by the noninflammatory fragment of 1633-171 of human interleukin 1β. J. Exp. Med. 168:675.
50. Tagliabue, A., and D. Boraschi. 1993. Cytokine as vaccine adjuvants: interleukin 1 and its synthetic peptide 163-171. Vaccine 11:594.
51. Lofthouse, S. A., A. E. Andrews, G. J. Barcham, and A. D. Nash. 1995. Parameters related to the application of recombinant ovine interleukin-1β as an adjuvant. Vaccine 13:1277.
52. Spangler, B. D. 1992. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:622.
53. Lindner, J., A. F. Geczy, and G. J. Russell-Jones. 1994. Identification of the site of uptake of the E. coli heat-labile enterotoxin, LTB. Scand. J. Immunol. 40:564.
54. Bromander, A. K., M. Kjerrulf, J. Holmgren, and N. Lycke. 1993. Cholera toxin enhances alloantigen presentation by cultured intestinal epithelial cells. Scand. J. Immunol. 37:452.
55. Sutherland, D. B., G. W. Varilek, and G. A. Neil. 1994. Identification and characterization of the rat intestinal epithelial cell (IEC-18) interleukin-1 receptor. Am. J. Physiol. 266:C1198.
56. Varilek, G. W., G. A. Neil, and W. P. Bishop. 1994. Caco-2 cells express type I interleukin-1 receptors: ligand binding enhances proliferation. Am. J. Physiol. 267:G1101.
57. McGee, D. W., S. J. D. Vitkus, and P. Lee. 1996. The effect of cytokine stimulation on IL-1 receptor mRNA expression by intestinal epithelial cells. Cell. Immunol. 168:276.
58. Lycke, N., and J. Holmgren. 1986. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 59:301.
59. Dinarello, C. A. 1996. Biologic basis for interleukin-1 in disease. Blood 87:2095.
60. Dinarello, C. A. 1994. The interleukin-1 family: 10 years of discovery. FASEB J. 8:1314.
61. Dinarello, C. A. 1992. The biology of interleukin-1. Chem. Immunol. 51:1.
62. Krakauer, T. 1996. Evidence for protein kinase C pathway in the response of human peripheral blood mononuclear cells to cholera toxin. Cell. Immunol. 172:224.
63. O'Neill, L. A. J. 1995. Towards an understanding of the signal transduction pathways for interleukin 1. Biochim. Biophys. Acta. 1266:31.
64. Bankers-Fulbright, J. L., K. R. Kalli, and D. J. McKean. 1996. Interleukin-1 signal transduction. Life Sci. 59:61.
65. Rinehart, J., E. Hersh, B. Issell, P. Triozzi, W. Buhles, and J. Neidhart. 1997. Phase 1 trial of recombinant human interleukin-1β (rhIL-1β), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology Group Study 8940. Cancer Invest. 15:403.
66. Verschraegen, C. F., A. P. Kudelka, W. Termrungruanglert, C. G. de Leon, C. L. Edwards, R. S. Freedman, J. J. Kavanagh, and S. Vadhan-Raj. 1996. Effects of interleukin-1α on ovarian carcinoma in patients with recurrent disease. Eur. J. Cancer 32A:1609.
67. Janik, J. E., L. L. Miller, D. L. Longo, G. C. Powers, W. J. Urba, W. C. Kopp, B. L. Gause, B. D. Curti, R. G. Fenton, J. J. Oppenheim, et al. 1996. Phase II trial of interleukin 1 α and indomethacin in treatment of metastatic melanoma. J. Natl. Cancer Inst. 88:44.
68. Weisdorf, D., E. Katsanis, C. Verfaillie, N. K. C. Ramsay, R. Haake, L. Garrison, and B. R. Blazar. 1994. Interleukin-1α administered after autologous transplantation: a phase I/II clinical trial. Blood 84:2044.
69. Nemunaitis, J., F. R. Appelbaum, K. Lilleby, W. C. Buhles, C. Rosenfeld, Z. R. Zeigler, R. K. Shadduck, J. W. Singer, W. Meyer, and C. D. Buckner. 1994. Phase I study of recombinant interleukin-1 β in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia. Blood 83:3473.
70. Veltri, S., and J. W. Smith, Jr. 1996. Interleukin 1 trials in cancer patients: a review of the loxicity, antitumor and hematopoietic effects. Stem Cells 14:164.
71. Zelterstrom, M., J. Lundkvist, D. Malinowsky, G. Eriksson, and T. Bartfai. 1998. Interleukin-1-mediated febrile responses in mice and interleukin-1β activation of NFκB in mouse primary astrocytes, involves the interleukin-1 receptor accessory protein. Eur. Cytokine Network 9:131.
72. Swiergiel, A. H., G. N. Smagin, and A. J. Dunn. 1997. Influenza virus infection of mice induces anorexia: comparison with endotoxin and interleukin-1 and the effects of indomethacin. Pharmacol. Biochem. Behav. 57:389.
73. Zheng, H., D. Fletcher, W. Kozak, M. Jiang, K. J. Hofmann, C. A. Conn, D. Soszynski, C. Grabiec, M. E. Trumbauer, A. Shaw, et al. 1995. Resistance to fever induction and impaired acute-phase response in interleukin-1 β-deficient mice. Immunity 3:9.
74. Osaki, T., J.-M. Peron, Q. Cai, H. Okamura, P. D. Robbins, M. Kurimoto, M. T. Lotze, and H. Tahara. 1998. IFN-γ-inducing factor/IL-18 administration mediates IFN-γ-and IL-12-independent antitumor effects. J. Immunol. 160:1742.
75. McGee, D. W., C. O. Elson, and J. R. McGhee. 1993. Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines. Infect. Immun. 61:4637.
76. Panja, A., E. Siden, and L. Mayer. 1995. Synthesis and regulation of accessory/ proinflammatory cytokines by intestinal epithelial cells. Clin. Exp. Immunol. 100:298.